The reason for such nearly universal PLAC1 expression in breast and uterine tumors may be that these cancers are far more hormone sensitive than are the others so far reported, and there is evidence from breast cancers that one of the PLAC1 promoters, P2, is estrogen responsive. This evidence concerns the gene PLAC1 and tumor of uterus.